Evolus (EOLS) Restructuring Costs (2020 - 2025)

Evolus' (EOLS) quarterly Restructuring Costs came in at $1.4 million in Q3 2025, down 51.18% on a QoQ basis from $3.0 million in Q2 2020.

Evolus (EOLS) Restructuring Costs (2020 - 2025) Analysis & Trends

Evolus (EOLS) has 2 years of Restructuring Costs data on file, last reported at $1.4 million in Q3 2025.

Quarterly Restructuring Costs changed N/A year-over-year to $1.4 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (changed N/A YoY) and the FY2025 annual result came in at $1.4 million, changed N/A from the prior year.
Restructuring Costs slipped to $1.4 million in Q3 2025, from $3.0 million in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $1.4 million in Q3 2025 to a low of $1.4 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-
2	Teva Pharmaceutical Industries	42.98 Bn	39.32 Bn	2.15 Bn
3	Zoetis	31.53 Bn	29.86 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn
6	Viatris	18.74 Bn	17.85 Bn	1.46 Bn
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.12 Bn	9.95 Bn	-
10	Evolus	554.79 Mn	509.62 Mn	57.18 Mn

Download Data

Date	Value
Sep 30, 2025	1.44 Mn
Jun 30, 2020	2.96 Mn